Manufacturing Considerations for Mesenchymal Cells and Broader Allogeneic Modalities
Summary: Mesenchymal Cell (MSCs) therapies are being pursued in high-impact diseases, but scalability is still a challenge. At Catalent, we implement innovative manufacturing and fill & finish methodologies to accelerate the path to commercial for MSCs and other allogeneic modalities.